Open AccessChallenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer
Author(s) -
Diana Lüftner,
Andreas D. Hartkopf,
Michael P. Lux,
Friedrich Overkamp,
Hans Tesch,
Adriana Titzmann,
Patrik Pöschke,
Markus Wallwiener,
Volkmar Müller,
Matthias W. Beckmann,
Erik Belleville,
Wolfgang Janni,
Tanja Fehm,
HansChristian Kolberg,
Johannes Ettl,
D. Wallwiener,
Andreas Schneeweiß,
Sara Y. Brucker,
Peter A. Fasching
Publication year - 2021
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000515701
Subject(s) - medicine , breast cancer , metastatic breast cancer , clinical trial , translational research , cancer , quality of life (healthcare) , oncology , pathology , nursing
Background: The therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data. Summary: To develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas. Key Messages: This article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation.